All Picks
Every pick with full AI analysis, catalyst research, and actionable signals.
Portfolio Value
$12,748
Total Return
+27.48%
Win Rate
46%
Avg Return
+8.1%
Active Positions
Avg: +4.70%Closed Positions
| Ticker | Entry | Exit | P&L |
|---|---|---|---|
| DAVE | $272.69 | $371.62 | +36.28% |
| WDC | $681.75 | $586.45 | -13.98% |
| NVDA | $219.35 | $195.74 | -10.76% |
| HBM | $29.09 | $25.37 | -12.80% |
| WDC | $462.32 | $653.53 | +41.36% |
| HBM | $29.05 | $25.66 | -11.68% |
| AVGO | $430.13 | $385.73 | -10.32% |
| MU | $967.66 | $864.01 | -10.71% |
| INDV | $38.25 | $33.72 | -11.84% |
| DELL | $244.15 | $318.24 | +30.35% |
| MU | $695.45 | $928.41 | +33.50% |
| RDW | $10.97 | $14.78 | +34.67% |
| MU | $764.72 | $681.54 | -10.88% |
| SQM | $92.95 | $82.61 | -11.13% |
| ALB | $210.71 | $180.40 | -14.38% |
| DELL | $205.66 | $238.98 | +16.20% |
| RKLB | $81.93 | $117.35 | +43.23% |
| MU | $518.46 | $746.79 | +44.04% |
| MU | $514.48 | $746.79 | +45.15% |
| LRCX | $219.82 | $297.17 | +35.19% |
Pick Archive
argenx Is Knocking on Its 52-Week High With a Pipeline Full of Rockets
Here's a 1-sentence teaser: **argenx is freshly profitable, accelerating at triple-digit earnings growth, and sitting a breath away from all-time highs — with a loaded catalyst runway that makes the next 90 days look very interesting.**
Comfort Systems Is the Quiet Monster Behind the Data Center Boom
**The HVAC contractor quietly powering America's AI infrastructure just doubled its earnings, grew its backlog 81%, and almost nobody is talking about it.**
NBIX Is Knocking on Its 52-Week High, and the Fundamentals Justify a Breakout
Here's a 1-sentence teaser for the blog post: **Neurocrine Biosciences is quietly sitting just 2% below its 52-week high with a blowout quarter, a second blockbuster drug launch, and a forward P/E of only 13.4x — and the market hasn't noticed yet.**
Howmet Aerospace Is Printing Money and Wall Street Is Still Sleeping On It
**Howmet Aerospace just beat earnings, raised guidance by double digits, and is trading 7% off its highs with a PEG under 1.0 — and somehow Wall Street still hasn't fully priced it in.**
Micron Just Reported the Most Explosive Quarter in Semiconductor History. The Stock Is Still Cheap.
Here's a 1-sentence teaser: **Micron just posted 346% revenue growth and 85% gross margins — and somehow, the market still hasn't fully priced it in.**
Credicorp Is Running on Rocket Fuel and the Market Hasn't Caught Up Yet
Here's a 1-sentence teaser: **Credicorp just delivered a jaw-dropping earnings beat, yet the stock is still trading 4% below its 52-week high — and with a forward P/E of just 11.3x, the market may be handing you a rare opportunity before the next catalyst hits on August 13.**
Micron Just Printed the Most Important Earnings Report in Semiconductor History
Here's a 1-sentence teaser: **Micron just obliterated Wall Street estimates with an EPS of $25.11 against a $20.49 forecast and revenue of $41.46B against a $35.69B estimate — and if you think this 15% after-hours rip is the whole story, you haven't seen what eight consecutive beats and an AI-driven demand surge actually mean for where this stock is headed.**
Comfort Systems Is Printing Money and Wall Street Is Just Waking Up
Here's a 1-sentence teaser for the blog post: **Comfort Systems USA just crushed earnings while trading 5% below its 52-week high — and with a catalyst-packed July 23 earnings date on the horizon, the window to get in before Wall Street fully wakes up is closing fast.**
Lam Research Is Riding the AI Wave, and the Chart Is Starting to Agree
Here's a 1-sentence teaser for the blog post: **Lam Research just posted record revenue, raised guidance above consensus, and is still trading 10% below its 52-week high — and with earnings just 35 days away, this AI-driven setup may not stay under the radar for long.**
Beam Therapeutics Is Quietly Becoming One of the Most Exciting Biotech Plays of 2026
Here's a 1-sentence teaser for the blog post: **Beam Therapeutics has nearly doubled off its lows and could have another 50% upside ahead — here's why this under-the-radar base editing pioneer might be one of biotech's most compelling setups heading into 2026.**
Lam Research Is the Backbone of the AI Hardware Boom, and It's Still Cheap Enough to Buy
Here's a 1-sentence teaser: **While everyone chases Nvidia, Lam Research is quietly powering the entire AI chip-making machine — and with the stock still 9% off its highs, the real picks-and-shovels play might be hiding in plain sight.**
Beam Therapeutics Is Quietly Building One of the Best Pipelines in Biotech
Here's a 1-sentence teaser: **Beam Therapeutics owns the patent on base editing — the next evolution of gene therapy — and with FDA clearance secured, pivotal trial data on the horizon, and analysts pricing the stock 54% higher than where it trades today, this quietly-building biotech giant may be the most compelling risk/reward in the sector right now.**
Pampa Energía Is Printing Money and Nobody's Talking About It
**Pampa Energía just blew past earnings estimates by 138%, trades at a laughably cheap 6x forward P/E, and almost nobody is paying attention — yet.**
Micron Is About to Tell You Everything, So Don't Jump In Yet
Here's a 1-sentence teaser for the post: **Micron's AI-fueled surge looks irresistible right now — but with earnings just 48 hours away and the stock flirting with overbought territory, jumping in today could be the most expensive impatience of your year.**
PAM Just Crushed Earnings - Argentina's Energy Giant Is Cheap at These Levels
Pampa Energía (PAM) just demolished earnings expectations with a 138% Q1 beat while trading at a bargain 10.7x P/E, presenting a compelling 32% upside opportunity as analysts eye $116 price targets on this undervalued Argentine energy powerhouse.
Micron Is Coiled Like a Spring - But Hold Your Fire
Despite Micron's explosive 850% rally from its lows and compelling technical setup near $982, smart money should wait for post-earnings volatility to subside before pulling the trigger on this coiled spring.
RDW: Space Stock Crashes Into a Buying Zone
Space infrastructure play Redwire (RDW) just crashed 10.5% after earnings in a classic market overreaction, creating a compelling buying opportunity as investors ignore the company's record backlog growth while focusing on short-term noise.
Datadog's $1B Quarter Changes Everything
Datadog just shattered the $1 billion quarterly revenue barrier for the first time, triggering a massive 31% pre-market surge that validates its critical role as AI infrastructure backbone—but with RSI at 85+ levels, timing your entry becomes everything.
BEAM: Earnings Surprise King Sitting at an Inflection Point
Beam Therapeutics just delivered a shocking earnings beat and sits at a critical inflection point with Q1 results imminent—making this gene editing stock either your next big winner or a harsh lesson in biotech volatility.
Jazz Pharma Just Crushed Earnings and the Momentum is Building
Jazz Pharmaceuticals just demolished Q1 expectations and rocketed 134% in the past year, but with the stock trading just $2.50 off its 52-week highs and technical momentum screaming higher, this biotech powerhouse might just be getting started.
BEAM: Prime Base Editing Play, But Wait for the Right Entry
Beam Therapeutics' base editing technology has Wall Street's attention after beating earnings, but at $31.77, savvy investors should wait for a better entry point below this resistance zone.
GameStop's Profit Machine is Back - Time to Buy the Dip
GameStop just crushed earnings with Walmart-level efficiency while trading 30% below its 52-week high, creating a compelling buy-the-dip opportunity before earnings in just 34 days.
SQM Is Riding the Lithium Recovery Wave Back to $100+
After swinging from a crushing $404M loss to a stunning $588M profit comeback, Chilean lithium giant SQM is breaking out near 52-week highs and positioning itself to ride the recovering lithium market straight back to $100+ as the next EV battery boom takes hold.
AVGO: Riding the AI Wave to New Highs
Broadcom (AVGO) is trading just $3 from its 52-week high after crushing earnings, positioning itself as a prime beneficiary of the exploding AI infrastructure boom with our analysts issuing a BUY signal and 63.55/100 conviction score.
ING Just Smashed Earnings and Announced a €1B Buyback - Time to Buy European Banking
While Wall Street fixates on U.S. banks, Dutch banking giant ING just delivered a knockout Q1 earnings beat paired with a confidence-screaming €1B share buyback that could make it Europe's most undervalued financial play.
Chewy's Profit Machine is Just Getting Started
Chewy just delivered a shocking 35% earnings beat while trading at half its 52-week high, positioning the pet retail giant at a profitability inflection point that could send shares soaring from their oversold levels.
Rocket Lab's Earnings Runway Looks Clear for Takeoff
Rocket Lab's record 2025 numbers have Wall Street scrambling to catch up, and with earnings dropping next week plus momentum hitting 77.5/100, this aerospace stock could be ready for serious liftoff from its current $81.93 price point.
Broadcom's AI Gold Mine is Just Getting Started
Broadcom's AI revenue just doubled to $8.4 billion with another 47% surge forecasted next quarter, positioning this chip giant as the prime beneficiary of hyperscalers' insatiable appetite for custom AI accelerators.
Micron's AI Memory Goldmine is Just Getting Started
Micron's AI memory dominance is accelerating with another crushing quarter, and at $514 (down from $531 highs), this pullback could be your last chance to board before the next explosive leg up in the AI revolution.
TSM's AI Wave Isn't Over — Momentum Building Into Q2
While AI stocks capture headlines, Taiwan Semiconductor (TSM) is quietly positioning for another breakout with 58% earnings growth and fresh momentum building as the chip cycle accelerates into Q2.
BEAM Therapeutics: Gene Editing Giant Ready to Launch
BEAM Therapeutics is positioned for a breakout with fresh Phase 1/2 liver disease data, a massive $500 million funding boost, and upcoming earnings that could catalyze the gene-editing pioneer's transition from promising biotech to commercial powerhouse.
Uranium Giant Cameco Coils for Major Breakout - Earnings Could Be The Trigger
Uranium giant Cameco sits just days away from potentially explosive Q1 2026 earnings that could trigger a major breakout from its $116.50 perch, with three consecutive quarters of earnings beats and surging global nuclear demand creating the perfect storm for another monster move.
BEAM Could Be the Next Biotech Breakout - But Not Yet
Beam Therapeutics is sitting on a powder keg with a 76% analyst upside target and earnings just 8 days away, but smart money is waiting for the right technical trigger before jumping in.
Uranium Giant CCJ Coils for Breakout as Earnings Loom
Uranium giant Cameco (CCJ) sits poised for a potential breakout just 8 days before earnings, having surged 181% from its lows while institutional investors quietly accumulate shares near multi-year highs.
Beam Therapeutics: The Gene Editor That Just Beat Earnings by $3.46
**BEAM Therapeutics just crushed earnings expectations by $3.46 and with their next report dropping in just 11 days, this gene editing biotech could be setting up for a major breakout from the middle of its trading range.**
Jazz Pharmaceuticals: Watching for the Q1 Earnings Setup
Jazz Pharmaceuticals sits at a compelling crossroads with Q1 earnings just 11 days away, trading at a dirt-cheap 7.8x forward P/E while hovering near 52-week highs—a setup that could trigger the next leg up for this biotech standout.
Comfort Systems USA: Waiting for Earnings Dust to Settle
**Comfort Systems USA has skyrocketed 400% from its lows but with RSI at overbought levels of 72.6 and earnings dropping today, this HVAC powerhouse needs a technical cooldown before becoming a compelling buy.**
Gene Editing Giant Beam Primed for Next-Level Catalyst
Beam Therapeutics (BEAM) sits at a compelling inflection point just 12 days before earnings, trading 18% below its 52-week high despite delivering a massive February surprise that has patient gene-editing investors watching closely for the next catalyst.
Comfort Systems USA: Don't Chase This HVAC Giant (Yet)
Despite crushing earnings and raising its dividend, Comfort Systems USA (FIX) has rocketed 387% to near all-time highs at $1,718 per share, making this HVAC giant a dangerous chase trade with an overbought RSI of 70 heading into tomorrow's earnings report.
BEAM: Biotech Darling on Earnings Watch Before Q1 Print
Beam Therapeutics (BEAM) sits at a critical technical juncture with Q1 earnings just 13 days away, having crushed February expectations by $3.46 per share while trading near resistance levels that could spark the next major breakout in this gene editing pioneer.
Rocket Lab's Revenue Rocket Takes Flight
Rocket Lab's explosive Q4 revenue growth of 36% to $180 million, combined with bullish technicals showing an RSI of 67.63, positions RKLB as a prime buy at $87.81 as the space economy reaches new heights.
Comfort Systems USA: Riding High Into Earnings, But Wait for the Right Entry
Despite crushing Q4 earnings with a 41.7% revenue surge, Comfort Systems USA (FIX) at $1,686 presents a classic momentum versus valuation dilemma—discover why our 62.33 score signals "WAIT" and how to time the perfect entry before earnings drop.
TSM Earnings Eve: The $400 Question Mark
Will Taiwan Semiconductor's earnings tomorrow justify analysts' sky-high $439 price target, or is this chip giant's 160% rally from $145 finally hitting a wall at $377?
GE's $190B Backlog Sets Up Perfect Pre-Earnings Play
With GE Aerospace's massive $190 billion backlog fueling expectations and earnings just 6 days away, this pullback from 52-week highs might be the perfect entry point for a pre-earnings momentum play.
Taiwan Semi: Wait for the Earnings Dip Before Loading Up
Despite Taiwan Semi's blistering 45% YoY sales growth and proximity to 52-week highs, savvy investors should resist FOMO and wait for the inevitable post-earnings volatility to create a better entry point in this chip powerhouse.
GE Aerospace: Earnings Week Could Be the Catalyst for $350+
GE Aerospace sits just $36 away from analyst targets at $353, and with earnings dropping April 21st following their monster 26.4% Q4 revenue beat, this could be the breakout catalyst that sends shares soaring past $350.
TSM: The AI King Needs to Clear One More Hurdle
Taiwan Semiconductor (TSM) trades just 5% off its 52-week high with earnings three days away, creating a perfect storm where the AI chip king's undisputed dominance meets a critical timing decision that could make or break your entry point.
IRTC: Cardiac Monitor King Trading at a Discount After Earnings Overreaction
iRhythm Technologies (IRTC) crushed earnings but got unfairly punished by the market, creating a compelling buying opportunity for the cardiac monitoring leader trading 46% below its 52-week high just 17 days before its next earnings report.
DigitalOcean Breaks Out After Crossing $1B Revenue Milestone
DigitalOcean's explosive 150%+ AI customer growth and breakthrough $1B revenue milestone has the stock breaking out of consolidation at the perfect technical setup, making it a compelling buy ahead of earnings season.
TSM: The AI Giant Sitting at a Critical Inflection Point
Taiwan Semiconductor (TSM) sits just 5% from its 52-week high with earnings six days away, but savvy investors should resist the FOMO—this AI powerhouse's stalling momentum and critical technical resistance levels suggest waiting for post-earnings clarity could be the difference between catching a breakout and catching a falling knife.